Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide

Luca Castagna, Roberto Crocchiolo, Sabine Furst, Stefania Bramanti, Jean El Cheikh, Barbara Sarina, Angela Granata, Elisa Mauro, Catherine Faucher, Bilal Mohty, Samia Harbi, Christian Chabannon, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.

Original languageEnglish
Pages (from-to)724-729
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Peripheral Blood Stem Cell Transplantation
Cyclophosphamide
Graft vs Host Disease
Transplantation
Bone Marrow
Incidence
Stem Cells
Bone Marrow Transplantation
Platelet Count
Neutrophils
Tissue Donors
Survival
Mortality
Peripheral Blood Stem Cells

Keywords

  • Haploidentical transplantation
  • Postinfusion cyclophosphamide
  • Stem cell sources

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide. / Castagna, Luca; Crocchiolo, Roberto; Furst, Sabine; Bramanti, Stefania; El Cheikh, Jean; Sarina, Barbara; Granata, Angela; Mauro, Elisa; Faucher, Catherine; Mohty, Bilal; Harbi, Samia; Chabannon, Christian; Carlo-Stella, Carmelo; Santoro, Armando; Blaise, Didier.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 5, 2014, p. 724-729.

Research output: Contribution to journalArticle

@article{745b2e360dfa4868b239abb1175ec195,
title = "Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide",
abstract = "Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33{\%} versus 25{\%}, respectively, and the incidence of chronic GVHD was 13{\%} versus 13{\%}, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12{\%} versus 22{\%}, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.",
keywords = "Haploidentical transplantation, Postinfusion cyclophosphamide, Stem cell sources",
author = "Luca Castagna and Roberto Crocchiolo and Sabine Furst and Stefania Bramanti and {El Cheikh}, Jean and Barbara Sarina and Angela Granata and Elisa Mauro and Catherine Faucher and Bilal Mohty and Samia Harbi and Christian Chabannon and Carmelo Carlo-Stella and Armando Santoro and Didier Blaise",
year = "2014",
doi = "10.1016/j.bbmt.2014.02.001",
language = "English",
volume = "20",
pages = "724--729",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide

AU - Castagna, Luca

AU - Crocchiolo, Roberto

AU - Furst, Sabine

AU - Bramanti, Stefania

AU - El Cheikh, Jean

AU - Sarina, Barbara

AU - Granata, Angela

AU - Mauro, Elisa

AU - Faucher, Catherine

AU - Mohty, Bilal

AU - Harbi, Samia

AU - Chabannon, Christian

AU - Carlo-Stella, Carmelo

AU - Santoro, Armando

AU - Blaise, Didier

PY - 2014

Y1 - 2014

N2 - Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.

AB - Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.

KW - Haploidentical transplantation

KW - Postinfusion cyclophosphamide

KW - Stem cell sources

UR - http://www.scopus.com/inward/record.url?scp=84897957070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897957070&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.02.001

DO - 10.1016/j.bbmt.2014.02.001

M3 - Article

VL - 20

SP - 724

EP - 729

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -